ABSTRACT
Tamoxifen [TAM] is a synthetic antiestrogen commonly used to treat breast cancer in women. TAM-induced hepatotoxicity has been described, including toxic hepatitis, massive hepatic steatosis, or multifocal hepatic fatty infiltration. Tea is one of the most popular beverages consumed worldwide. Some studies indicated that green tea prevents hepatotoxicity and has antitumorigenic effects. The aim of the study was to evaluate the protective effects of green tea extract [GTE] against TAM-induced liver injury in rats. Forty adult male albino rats were divided into four groups [10 rats each]: the control group; the green tea group, administered 1.5% GTE orally for 18 days; the TAM group, treated with 45 mg/kg/day of TAM for 7 days; and the TAM and green tea group, administered 1.5% GTE 4 days before and 14 days after TAM treatment. Animals were sacrificed at the end of the experiment. The livers were removed and processed for light microscopic examination. The TAM-treated group showed loss of normal architecture of hepatic lobules, hemorrhage, cholestasis, ballooning degeneration of hepatocytes, steatosis, inflammatory cells infiltration, Kupffer cells hyperplasia, and dilated and congested sinusoids and portal venules. Liver sections of the TAM and green tea-treated group showed normal architecture of hepatic lobules, portal triad, hepatocytes, central vein, and blood sinusoids. Green tea has protective effects against TAM-induced hepatotoxicity
Subject(s)
Male , Animals, Laboratory , Camellia sinensis/adverse effects , Protective Agents , Tamoxifen/toxicity , Microscopy, Polarization/statistics & numerical data , RatsABSTRACT
El tamoxifén es una droga antiestrogénica utilizada en el tratamiento de pacientes con cáncer de mama. Muchos estudios han reportado la toxicidad ocular causada por el tamoxifén en pacientes con síntomas visuales (disminución de la agudeza visual). Nuestro estudio determina la prevalencia de toxicidad ocular en pacientes visualmente asintomáticos que reciben tratamiento con tamoxifén a bajas dosis por tiempo prolongado (10 mg dos veces al día). Realizamos examen ocular a 30 pacientes asintomáticos visualmente. Dos pacientes (6,6 por ciento) presentaron cristales refráctiles en la retina, lo que se considera como la manifestación de la retinopatía por tamoxifén. Ninguno de los dos pacientes tuvieron disminución de la agudeza visual. Tampoco presentaron opacidades corneales, edema macular ni cambios a nivel del nervio óptico. La dosis total de tamoxifén en estos dos pacientes fue de 14,6 y 25,8 g. respectivamente. En los 30 pacientes estudiados, la dosis promedio fue de 19,92g. Un buen examen oftalmológico debe ser realizado a todos los pacientes que reciben terapia con tamoxifén